contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


aiforia-wins-new-clinical-segment-client-in-turkey

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Head of Nordic ER Development, Analyst

Antti Luiro

Analyst

Frans-Mikael Rostedt

Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of fields such as oncology and neuroscience. Aiforia Technologies is headquartered in Finland.

This also restricts issues in January. Persons discharging managerial responsibilities at the issuer are subject to a 30-day closed period before the disclosure of an interim report or annual financial statements. During the closed period, a person discharging managerial responsibilities shall not conduct, on their own account or on behalf of a third party, directly or indirectly, transactions relating to the issuer’s shares or debt instruments, or derivatives or other financial instruments related thereto. The closed period applies not only to the personal transactions of a person discharging managerial responsibilities but also to all situations where a person discharging managerial responsibilities carries out transactions on behalf of their closely associated persons, such as their controlled entity, or a third party.

Will that ownership list be updated before trading begins with these new shares on the 15th, or will it only be visible at the beginning of January, as is usually the case to see where the shares have settled?

Someone said it would have been better to wait until January with the offering, perhaps for the sake of the share price, but has anyone ever arranged an offering in January, such that the management might know the financial statement figures, but they are not yet public to investors? The subscriber could demand their money back, along the lines of, management withheld information about poor results. Now management can always say, we thought we would still get big orders in the last two weeks..if Aiforia’s financial statement figures turn out to be chilling..

Aiforia Technologies Plc – Manager’s transactions – Tuomas Tenkanen Aiforia Technologies Plc TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES 12 December 2025 at 1:00 PM Tenkanen subscribed for 283979 shares. The average price is 2.106 Total 596355 EUR

It seems the offering didn’t sell very well, as Tenkanen ended up with more shares than his original commitment:  TJT Technologies Oy, a company controlled by Tuomas Tenkanen, a member of Aiforia’s Board of Directors, has given its irrevocable commitment to subscribe for Shares for at least 500,000 euros in the Share Offering, conditional on certain terms.   Volume: 283979 Average price: 2.106 EUR

This probably does meet the characteristics of a crisis company, when a directed share issue is discussed. Otherwise, next year they would have to shut down. A larger public share issue, on the other hand, is often a fairly sure way to crash the stock price (e.g., Exel composities). Or perhaps one might have even hoped for it now as a potential new owner, because through warrants, one often gets shares cheaply then. The larger the issue and the more warrants come onto the market, the bigger the crash…

Based on the tone of your text, you seem agitated, so now would be a good time to breathe in and out and calm down a bit, so that the constructive spirit of the discussion can continue. Naturally, the Aiforia thread also includes discussion about the company’s announcement to arrange a directed share issue. Where else should Aiforia’s issue be discussed, if not in the Aiforia thread? It’s a shame you didn’t find the Finnlines example interesting, even though it’s a prime example of the problem with directed share issues. However, this is not my own invention, as you claim, but for example, the Finnish Shareholders’ Association (Suomen Osakesäästäjät), which also advocates for your interests, has often brought up the same issue: \u003eSaving on capital acquisition costs is not a compelling financial reason to deviate from pre-emptive rights.  \u003e  \u003eA directed issue is always faster and cheaper to implement than a rights issue. This was by no means the legislator’s intention when creating the law. The purpose of the law has rather been, for example, to rescue a crisis company or to offer shares as consideration to the owners of an acquired target in connection with an acquisition. Neither of these applies to Remedy Entertainment.  \u003e  \u003eIn addition, the realized issue price has been lower than the closing price of the previous day, i.e., the price corresponding to the company’s market value. Thus, from the shareholders’ perspective, the cost of the issue has been the difference between the issue price and the stock market price.  \u003e  \u003e Clarification is required for legislation  \u003e  \u003eThe Finnish Shareholders’ Association (Suomen Osakesäästäjät) will bring the case to the attention of the legislator, because the method can be used even arbitrarily without intervention. Legislation must therefore be clarified as to what constitutes a compelling financial reason from the company’s perspective.                   Suomen Osakesäästäjät – 19 Feb 21              Suunnattu osakeanti ja Remedy Entertainment    Suomen Osakesäästäjät on lähtökohtaisesti hyvin skeptinen suunnattujen osakeantien suhteen. Sellaisen käytön täytyy olla hyvin poikkeuksellista, esimerkiksi liiketoimintakaupoissa sellaista voidaan…                             You might not have been aware, but a few years ago there was a major lawsuit where a key factor was the threat of arranging a directed issue. It’s worth checking out:                   Helsingin Sanomat – 14 May 21              Yrityskaupat | Ahlstrom-Munksjö ostettiin pörssistä, nyt hankkeesta on...    Ahlstrom-Munksjön suuromistajat ovat kertoneet velkasijoittajille huomattavasti houkuttavampia tunnuslukuja ja tarinaa kuin mitä yhtiön viralliset luvut osoittavat. Nyt Ahlström Capital vastaa kritiikkiin.

Aiforia Technologies

Memorial Hospitals Group in Turkey has selected Aiforia as its partner for AI-assisted clinical diagnostics in pathology. Memorial Hospitals Group is the largest private hospital group in Turkey, serving 75,000 patients annually in 11 hospitals.

Translation: Original published in Finnish on 12/2/2024 at 4:24 pm EET.
According to a&#xa0;<a href="https://www.inderes.se/releases/memorial-hospitals-group-in-turkey-selects-aiforia-as-the-partner-for-ai-assisted-clinical-diagnostics-in-pathology">press release</a>, Memorial Hospitals Group in Turkey has selected Aiforia as its partner for AI-assisted clinical diagnostics in pathology. Memorial Hospitals Group is the largest private hospital group in Turkey, serving 75,000 patients annually in 11 hospitals. The collaboration will utilize Aiforia&apos;s regulatory-approved clinical AI solutions to analyze biopsies from breast, prostate and lung cancer patients at the Memorial Pathology Center laboratory. 
According to the press release, Memorial Pathology is the first pathology laboratory in Turkey with a fully digital workflow and all biopsy samples are digitalized. This phase is required to implement Aiforia&apos;s image analysis solutions and is often time-consuming, but with a fully digital setting, the customer could start generating revenue for Aiforia as early as the beginning of 2025. We have included new deals in our forecasts and have been waiting for the company to announce them, so this release does not come as a surprise or put immediate pressure on our forecasts. Of course, the announcement supports our forecasts and is another sign that Aiforia&apos;s solution is competitive in the market and that the market development in Europe will continue.

	2023	24e	25e
Revenue	2.4	3.4	5.8
growth-%	49.3 %	41.2 %	71.1 %
EBIT (adj.)	-12.9	-12.1	-11.8
EBIT-% (adj.)	-537.1 %	-358.4 %	-204.4 %
EPS (adj.)	-0.50	-0.42	-0.41
Dividend	0.00	0.00	0.00
Dividend %
P/E (adj.)	neg.	neg.	neg.
EV/EBITDA	neg.	neg.	neg.

Aiforia wins new clinical segment client in Turkey

Key Estimate Figures2024-10-02

Forum discussions